Evidence map›Paper›PMID 38411531›Full record

ArticleBioconjugate chemistry2024

Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [

Wilson Lin, German Oscar Fonseca Cabrera, Eduardo Aluicio-Sarduy, Todd E Barnhart, Jason C Mixdorf, Zibo Li, Zhanhong Wu, Jonathan W Engle

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. Pharmaceutics · 2025
    Article
  6. Article
  7. Review
  8. Scalability study on [EJNMMI radiopharmacy and chemistry · 2024
    Article
  9. Synthesis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wilson LinDepartment of Medical Physics, University of Wisconsin, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.ORCID 0000-0003-4049-9355
German Oscar Fonseca CabreraDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Eduardo Aluicio-SarduyDepartment of Medical Physics, University of Wisconsin, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.
Todd E BarnhartDepartment of Medical Physics, University of Wisconsin, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.
Jason C MixdorfDepartment of Medical Physics, University of Wisconsin, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.
Zibo LiDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-1063-0298
Zhanhong WuDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jonathan W EngleDepartment of Medical Physics, University of Wisconsin, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.ORCID 0000-0002-3399-7228
University of Wisconsin–Madison · USUniversity of North Carolina at Chapel Hill · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KIM, KYUNGMANN · 2020 to 2024
$12.5M
The development of novel radiation-sensitizer based on ultra-small carbon dotsR01CA247769 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, XIE, JIN · 2020 to 2024
$2.5M
Novel Catalytic Methods for Efficient Radiolabeling of Un-activated Arene Compounds SupplementR01EB029451 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, NICEWICZ, DAVID A · 2020 to 2023
$2.2M
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancerR01CA257851 · NCI · UNIVERSITY OF GEORGIA · PI KIM, WILLIAM Y., LI, ZIBO · 2021 to 2024
$2.1M
The development of novel PET/NIRF agents for hyperparathyroidism managementR01DK128447 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM, LAWRENCE THOMAS, WU, ZHANHONG · 2021 to 2024
$2.0M
NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA247769NCI NIH HHS R01 CA257851NIBIB NIH HHS R01 EB029451NIDDK NIH HHS R01 DK128447
6 · The paper itself

Abstract

Cobalt-sarcophagine complexes exhibit high kinetic inertness under various stringent conditions, but there is limited literature on radiolabeling and in vivo positron emission tomography (PET) imaging using no carrier added

Indexed as

Cobalt RadioisotopesCyclotronsNeoplasmsAnimalsCell Line, TumorCopper RadioisotopesHeterograftsHumansMicePositron-Emission TomographyRadiopharmaceuticalsTissue DistributionCobalt-55Cobalt RadioisotopesCopper RadioisotopesRadiopharmaceuticals

Identifiers

PMID38411531
PMCPMC10954389
OpenAlexW4392182949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.